A first-of-its-kind clinical trial launched in the UK could cut years from the search for treatments for people with Alzheimer’s disease.
The Alzheimer’s disease systematic multi-arm adaptive randomised trial (AD-SMART) will test drugs simultaneously and will start with two repurposed medicines already used in the NHS to treat Type 2 diabetes and attention deficit hyperactivity disorder (ADHD).
AD-SMART will examine whether existing treatments, metformin (Type 2 diabetes) and atomoxetine (ADHD), could lessen symptoms of Alzheimer’s disease such as memory and thinking problems. The study will also assess whether they can help people maintain their quality of life as the disease progresses.
The two drugs were chosen by an international panel of experts together with people with lived experience of Alzheimer’s, based on evidence from early-stage studies in patients as well as laboratory research.
Accelerated testing of treatments
Both drugs may help to reduce brain inflammation, which is a driver of neurodegeneration, said Paresh Malhotra, professor of clinical neurology, chief investigator of AD-SMART, and group leader at the UK Dementia Research Institute (UK DRI) Centre for Care Research & Technology at Imperial College London.
“For too long, Alzheimer’s research has moved at the pace of one drug, one trial, one answer, sometimes taking a decade or more before we know if we’ve found something that works,” he explained.
“We are applying advances from cancer and other conditions to accelerate testing of treatments for people with Alzheimer’s disease. The way AD-SMART is set up means we’re testing several treatments at the same time, and those that don’t show promise can be quickly stopped. Then we can start testing something else. That’s the best way to get effective treatments to patients as quickly as we can.”
The study aims to recruit 1,200 patients with mild to moderate Alzheimer’s to test the two repurposed drugs initially. Patients will be recruited at more than 30 sites across the UK. Sites at Cambridge and Peterborough NHS Trust, Surrey and Borders Partnership NHS Trust, Imperial College Healthcare NHS Trust, Edinburgh and Southampton are already open.
Hope for the future
One of the first trial participants is Heather Ransome, 67, who was diagnosed with Alzheimer’s in 2024. Prior to her diagnosis, she enjoyed going on cruises and coach holidays with her partner. She now worries about her condition getting worse, but has hope for the future.
“I’m not the sort of person who gets upset, but being told you have Alzheimer’s is quite upsetting,” she said. “There weren’t many treatment options available, and the one drug I was offered has been around for many years.
“Getting involved with AD-SMART has given me some hope for the future,” she added. “It’s not too taxing, just some extra tablets to take every day. I don’t know whether I’m being given the active treatment, but if it helps me, or helps others in the future, that feels positive. I would encourage anyone who thinks they might be eligible to sign up and speak to the team.”
In addition to testing repurposed drugs, the trial will also introduce new drugs as they become available due to the way SMART trials are set up.
“We already know this model works,” said Siddharthan Chandran, professor of neurology and director of UK DRI. “The SMART approach, used by MND-SMART (a similar platform trial for motor neuron disease), has shown that testing multiple drugs at one time, in one smart trial design, can speed up the testing of new treatments for neurodegenerative conditions. Now, we’re doing the same for Alzheimer’s. And because of the way SMART trials are designed, biotech and pharmaceutical companies can also bring their drugs straight into the trial. That means more treatments can be tested more quickly, and for people living with Alzheimer’s, that could make all the difference.”
The AD-SMART team expect to finish evaluating the first drugs in 2030, and during that time, additional drugs are likely to be added to the trial for testing.



